This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1093/annonc/mdz453.002
Other

KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

..., Marina Chiara Garassino
63
Annals of Oncology56.70
Volume: 30, Pages: xi64 - xi65
Published: Dec 1, 2019
Abstract
No abstract.
Paper Fields
Paper Details
Title
KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
DOI
doi.org/10.1093/annonc/mdz453.002
Published Date
Dec 1, 2019
Journal
Annals of Oncology
Volume
30
Pages
xi64 - xi65
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.